TEVA withdraws $40 billion hostile take-over bid against Mylan

TEVA announced on July 27th its intention to withdraw its unsolicited expression of interest to acquire rival Mylan N.V., a leading global pharmaceutical company with a growing portfolio of around 1,400 generic pharmaceuticals and brand medications.

A CRA team provided economic support to Mylan in its antitrust defense in front of the European Commission against the attempted hostile take-over.